DRAPER, Utah, Jan. 27, 2014 /PRNewswire/ -- Nutranomics, Inc. (OTCBB: NNRX) (OTCQB: NNRX) ("Nutranomics" or the "Company") is pleased to announce that the Company has received an initial purchase order from UNO International Corp. ("UNO"), a leading health and natural products distributor in the Philippines.
The initial purchase order for 20,000 bottles of a Nutranomics developed enzyme product is expected to be sold throughout the Philippines by UNO's established network of distributors.
"We are confident that this initial purchase order for one of our extremely popular Nutranomics enzyme formulations will be the first of many from UNO," stated Dr. Tracy K. Gibbs, CEO of Nutranomics. "Following this successful launch, we anticipate introducing several other exclusive Nutranomics developed products to the 1000's of UNO distributors all across the Philippines."
UNO International Corp. is the largest Philippines-based company engaged in the direct and multi-level distribution of health enhancing natural products and other services. UNO's products include Glutathione soaps as well as capsules and lotions, "8-in-1" coffee for well-being and immune system support, "Ultima-C" non-acidic Vitamin C, and "Fit Right" capsules with L-Carnitine, Green Tea and Ampalaya.
Nutranomics is a publicly traded company engaged in research and development of nutritional food products. In 1997, Nutranomics produced and branded its own product line, and began to sell to the retail outlets and to the public. Nutranomics has also produced formulas for hundreds of other companies. Nutranomics' mission is to increase human health and longevity through education and self-awareness. The Company has sales representatives throughout North America and Asia. Learn more about Nutranomics at www.nutranomics.com.
For further information regarding Nutranomics, Inc., please contact our investor relations representatives at email@example.com, or call toll-free (888) 616-3999.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements." Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products and operating as a development stage company, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
SOURCE Nutranomics, Inc.